

An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma

T Miyazaki^{*1}, H Kato¹, M Nakajima¹, A Faried¹, J Takita¹, M Sohda¹, Y Fukai¹, S Yamaguchi¹, N Masuda¹, R Manda¹, M Fukuchi¹, H Ojima¹, K Tsukada¹ and H Kuwano¹

¹Department of General Surgical Science (Surgery I), Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan

Tissue inhibitor of metalloproteinase-3 (TIMP-3) inhibits the activity of matrix metalloproteinase, which may play an important role in carcinoma invasion and metastasis. We have investigated the relationship between TIMP-3 reduction and clinicopathological factors in oesophageal squamous cell carcinoma (ESCC). We examined tissue specimens that had been removed from 90 patients with thoracic oesophageal cancer who had undergone surgery between 1983 and 2001. Immunohistochemical staining was performed by the standard streptavidin–biotin method. Immunostaining of TIMP-3 was seen in the cytoplasm of cancer cells and normal oesophageal epithelial cells, particularly in cells located in shallow areas of the tumour. TIMP-3 preserved (+), moderate (\pm), and reduced (–) cases accounted for 30, 27, and 33 of the 90 patients, respectively (33, 30, 37%). Significant correlations were observed between TIMP-3 expression and depth of tumour invasion ($P=0.001$), number of lymph node metastases ($P=0.003$), infiltrative growth pattern ($P=0.003$), and disease stage ($P=0.005$). The survival rates of patients with TIMP-3 (–) cancer were significantly lower than those of patients with TIMP-3 (+) and TIMP-3 (\pm) cancer ($P=0.0003$). The mean 5-year survival rates of patients with TIMP-3 (+), (\pm), and (–) were 50, 58, and 21%, respectively. In conclusion, decreased expression of TIMP-3 protein correlates with invasive activity and metastasis. This makes the prognosis for patients with cancer that has lost TIMP-3 significantly less favourable than that for patients with cancer that has maintained TIMP-3.

British Journal of Cancer (2004) **91**, 1556–1560. doi:10.1038/sj.bjc.6602185 www.bjcancer.com

Published online 5 October 2004

© 2004 Cancer Research UK

Keywords: oesophageal cancer; tissue inhibitor of matrix metalloproteinase 3 (TIMP-3); invasion; prognosis; immunohistochemistry

The extracellular matrix is an important structure in maintenance of tissue organisation and in the suppression of cellular proliferation and migration. Excess destruction of the extracellular matrix is associated with many pathologies, including atherosclerosis, rheumatoid arthritis, and cancer progression (Liotta *et al*, 1980; Tryggvason *et al*, 1987; Palletier *et al*, 1990). The intricate balance between net extracellular matrix deposition and degradation is controlled by a complex system of tightly regulated protease enzymes and their endogenous inhibitors. Matrix destruction is thought to be a key event in both the local invasion and distant metastasis associated with tumour progression, and genes that inhibit these processes may be useful for cancer therapy. Matrix metalloproteinases (MMPs), a family of Zn^{2+} metalloproteinases involved in the degradation of extracellular matrix macromolecules, are associated with tissue destruction under various pathological conditions. Previous experimental and clinicopathological studies have revealed a good correlation between expression of MMPs and invasive phenotype of tumour cells or frequency of metastasis (Stetler-Stevenson *et al*, 1993; Sato *et al*, 1994). Expression of

MMP-1, -2, -3, -7, and -9 in oesophageal cancer has already been reported (Shima *et al*, 1992; Ohashi *et al*, 2000). In addition, Ohashi *et al* (2000) have reported the expression of tissue inhibitor of MMP (TIMP)-1 and -2, MT1-MMP, and MT2-MMP by immunohistochemical staining.

The TIMPs are a family of molecules that inhibit the proteolytic activity of MMPs, which also play an important role in tumour invasion and metastasis (Sato *et al*, 1992; Miyagi *et al*, 1995; Wang *et al*, 1997).

TIMP-3 is a secreted 24-kDa protein that, unlike other TIMP family members, binds to the extracellular matrix. Its functions have been reported as inducing apoptosis of cancer cells (Ahonen *et al*, 1998; Baker *et al*, 1999), and suppressing tumour growth and angiogenesis (Anand-Apte *et al*, 1996, 1997; Bian *et al*, 1996). Furthermore, TIMP-3 expression decreases at the invasive edge of poorly differentiated adenocarcinoma of the human colon, which suggests that a regional loss of TIMP-3 may contribute to their increased invasiveness (Powe *et al*, 1997). However, the relationship between TIMP-3 expression and clinical features (tumour invasiveness, metastasis and prognosis) in patients with ESCC is not known.

In this study, an immunohistochemical analysis of TIMP-3 protein expression was performed to determine the relationship between TIMP-3 reduction and clinicopathological factors in ESCC.

*Correspondence: Dr T Miyazaki; E-mail: tatsuyam@showa.gunma-u.ac.jp
Received 1 April 2004; revised 26 July 2004; accepted 17 August 2004;
published online 5 October 2004

MATERIALS AND METHODS

Patients and tissue samples

The tissue specimens used had been removed from 90 patients with thoracic ESCC who had undergone surgery at Gunma University Hospital between 1983 and 2001. Written informed consent to participate in the study was obtained from each patient before surgery, according to the ethical guidelines of our university. All patients underwent potentially curative surgery without preoperative therapy. There were 76 men and 14 women, aged 40–78 years (mean age: 60.9 years). Tumour stages were classified according to the fifth edition of the TNM classification of the International Union against Cancer (UICC). Evaluation of tumour differentiation was based on histological criteria of the guidelines of the Japanese Society for Esophageal Diseases (1999). The mean postoperative follow-up period was 33.9 months (range: 6.2–192.2 months).

Specimens were fixed in 10% formaldehyde solution and embedded in paraffin. We examined sections that contained both a tumour-invasive portion and normal oesophageal epithelium.

Antibodies

The monoclonal antibody (Mab) specific for TIMP-3 (clone 136-13H4) was purchased from Daiichi Fine Chemical Co. Ltd., Toyama, Japan.

Immunohistochemistry

Immunohistochemical staining was performed by the standard streptavidin–biotin (SAB) method. Briefly, each 4- μ m tissue section was deparaffinised, then rehydrated and incubated with fresh 0.3% H₂O₂ in methanol for 30 min at room temperature. After rehydration through a graded ethanol series, the sections were autoclaved in 10 mM citrate buffer (pH 6.0) at 120°C for 5 min, then cooled to 30°C. After incubation with normal rabbit serum for 30 min, the tissue sections were removed by blotting. The sections were then incubated at 4°C overnight with anti-TIMP-3 Mab at a dilution of 1:800 in phosphate-buffered saline (PBS) containing 1% bovine serum albumin, then washed in PBS and incubated with secondary antibody for 30 min at room temperature. Immunohistochemistry was performed using a Histofine SAB-PO(M) kit (Nichirei, Tokyo, Japan). The chromogen was 3,3'-diaminobenzidine tetrahydrochloride, applied as a 0.02% solution containing 0.0055% H₂O₂ in 50 mM ammonium acetate – citric acid buffer (pH 6.0). The sections were lightly counterstained with haematoxylin. Negative controls were prepared by substituting normal mouse serum for primary antibody, and no detectable staining was evident.

Evaluation of immunostaining for TIMP-3 expression

We evaluated immunostaining of cancer cells in all layers of the oesophageal epithelium. When more than 80% of carcinoma cells in a given specimen were positively stained as well as normal epithelium in the same section, the sample was classified as TIMP-3 preserved (TIMP-3 (+)); when less than 30% were stained, as TIMP-3 reduced (TIMP-3 (–)); and when 30–80% of cells were stained, as TIMP-3 moderate (TIMP-3 (\pm)).

Statistical analysis

Statistical analysis was performed using unpaired two-group *t* test for age and number of lymph node metastases. The χ^2 test was used to analyse the effects of sex, differentiation, location, and TNM clinical classification. Survival curves were calculated by the Kaplan–Meier method, and analysis was carried out by the log-rank test.




Figure 1 Representative photomicrographs of tissue sections immunostained for TIMP-3. (A) TIMP-3 was detected in the cytoplasm of the basal cells, parabasal cells, and leucocytes in normal oesophageal epithelium (left side). In this case, TIMP-3 expression in the cancer cells (right side) was weaker than that in the normal epithelium. This case was regarded as TIMP-3-reduced ($\times 100$). (B) The arrowhead indicates primary oesophageal cancer with TIMP-3 protein expression ($\times 100$). This case was regarded as TIMP-3 preserved. (C) High-power view of the immunohistochemistry. TIMP-3 was detected in the cytoplasm of cancer cells ($\times 200$).




Figure 2 Representative photomicrographs of tissue sections immunostained for TIMP-3 ($\times 50$). Black arrowheads indicate deep areas of tumour invasion. Cancer cells from these areas did not express TIMP-3 protein. White arrowheads indicate shallow areas of tumour, where cancer cells expressed TIMP-3 protein.

RESULTS
Relationship between TIMP-3 expression and clinicopathological features

Tissue inhibitor of metalloproteinase-3 expression in ESCC was investigated by immunohistochemical analysis of formalin-fixed,

paraffin-embedded specimens using a TIMP-3 specific Mab. In normal oesophageal tissue, immunostaining of TIMP-3 was detected in the cytoplasm of the basal cells, parabasal cells and stromal cells (Figure 1A, B). Immunostaining of TIMP-3 was seen in the cytoplasm of all cancer cells (Figure 1B, C). Expression of TIMP-3 was preserved in shallow areas of the tumour, but it was

Table 1 The correlation between clinicopathological characteristics and TIMP-3 expression

Parameters	Total	TOMP-3 preserve (n = 30)	TOMP-3 moderate (n = 27)	TOMP-3 reduce (n = 33)	P-value
Age (mean ± s.d., years)	60.9 ± 8.3	60.9 ± 7.5	59.9 ± 8.2	61.8 ± 9.1	NS
Gender					
Male	76	23	23	30	0.295
Female	14	7	4	3	
Differentiation					
Well	22	7	6	9	0.957
Moderate	45	15	15	15	
Poor	23	8	6	9	
Location					
Upper	12	1	6	5	0.060
Mid-thora	55	21	18	16	
Lower	23	8	3	12	
TNM clinical classification					
T					0.001
T1	34	20	9	5	
T2	13	2	6	5	
T3	37	8	11	18	
T4	6	0	1	5	
N					0.108
N0	36	16	11	9	
N1	54	14	16	24	
M					0.147
M0	74	28	21	25	
M1	16	2	6	8	
Stage					
I	23	15	4	4	0.005
II	28	7	12	9	
III	23	6	5	12	
IV	16	2	6	8	
No. of lymph node metastases (mean ± s.d.)	—	1.3 ± 1.8	3.1 ± 5.9	2.5 ± 3.4	0.003
Lymphatic invasion					
ly (-)	28	13	7	8	0.206
ly (+)	62	17	20	25	
Blood vessel invasion					
v (-)	49	18	14	17	0.756
v (+)	41	12	13	16	
Infiltrative growth pattern					
inf α	22	14	2	6	0.003
inf β	60	12	23	25	
inf γ	8	4	2	2	
Intraepithelial spread					
ie (-)	45	14	10	21	0.111
ie (+)	45	16	17	12	
Intramural metastasis					
IM0	80	27	25	28	0.619
IM1	10	3	2	5	

s.d. = standard deviation.




Figure 3 Relationship between overall postoperative survival and TIMP-3 expression. Patients with TIMP-3-reduced cancer had a significantly poorer prognosis than those with TIMP-3 preserved or moderate expression (5-year survival rates: TIMP-3 reduced, 21%; TIMP-3 moderate, 58%; TIMP-3 preserved, 50%; $P = 0.0003$).

reduced in deep areas of the same tumour (Figure 2). TIMP-3 preserved, moderate, and reduced cases accounted for 30, 27, and 33 of the 90 patients, respectively (33, 30, 37%). The relationship between the clinicopathological characteristics of patients with ESCC and TIMP-3 expression is summarised in Table 1. A significant correlation was observed between TIMP-3 expression and depth of tumour invasion ($P = 0.001$), number of lymph node metastases ($P = 0.003$), infiltrative growth pattern ($P = 0.003$), and disease stage ($P = 0.005$). However, there was no significant association with age, sex, tumour location, presence of regional lymph node metastasis, lymphatic invasion, blood vessel invasion, intraepithelial spread, intramural metastasis, or presence of distant metastasis.

The survival rates of patients with TIMP-3 (–) cancer were significantly lower than those of patients with TIMP-3 (+) and TIMP-3 (±) cancer ($P = 0.0003$; Figure 3). The mean 5-year survival rates of patients with TIMP-3 (+), (±), and (–) were 50, 58, and 21%, respectively. Multivariate analysis showed that TIMP-3 overexpression was not a prognostic factor by itself, in contrast to depth of tumour invasion, lymph node metastasis, or disease stage (data not shown).

DISCUSSION

Our immunohistochemical results suggest that expression of TIMP-3 protein is correlated with depth of tumour invasion, the number of lymph node metastases and disease stage. The expression of TIMP-3 protein was localised in shallow areas of the tumour, and was reduced in deep areas of the same tumour. In particular, no expression was observed at the invasive tumour front. This result indicated that invading cancer cells had lost their expression of TIMP-3. Furthermore, the prognosis for patients with cancer that had lost TIMP-3 was significantly less favourable than that for patients with TIMP-3 (+) and TIMP-3 (±) cancer.

Bachman *et al* (1999) showed that loss of TIMP-3 expression is associated with dense methylation of the 5'-CpG island in cell lines from many common human cancers. This methylation-associated silencing of TIMP-3 is tumour-specific, and associated with lack of TIMP-3 protein expression in primary cancers. Aberrant methylation of *TIMP-3* was demonstrated in primary cancers of the kidney, brain, colon, breast, and lung, but not in any of 41 normal tissue samples. Reduced TIMP-3 expression in ESCC may also have been caused by aberrant methylation in our study.

Baker *et al* (Ahonen *et al*, 1998; Baker *et al*, 1999) reported that TIMP-3 expression inhibits invasion and induces apoptosis in cancer cells. They used adenovirus-mediated gene delivery of TIMP-1, -2, and -3 to melanoma, cervical carcinoma, and fibrosarcoma cell lines. Their reports support ours. Tissue inhibitor of metalloproteinase-3 expression may be unfavourable for the survival of cancer cells, and cancer cells with a high grade of malignancy (more invasive and fewer apoptotic cells) may not express TIMP-3 for various reasons.

An imbalance between cell surface-associated proteinases and their inhibitors (higher concentrations of MMPs and lower concentrations of TIMPs) has been traditionally implicated in tumour expansion. However, it has been reported that some TIMPs function as growth factors (Hayakawa *et al*, 1992, 1994). For example, TIMP-1 and TIMP-2 have erythroid potentiating activity, and accelerate the growth of most cells (Hayakawa *et al*, 1992, 1994). Tissue inhibitor of metalloproteinase-3 has been reported to stimulate the proliferation of growth-retarded, nontransformed cells maintained under low-serum conditions (Yang and Hawkes, 1992). These reports do not coincide with our data, but growth activity is not always consistent with invasive activity.

Other functions of TIMP-3 have been reported, including suppression of tumour growth and angiogenesis (Anand-Apte *et al*, 1996, 1997; Bian *et al*, 1996; Spurbeck *et al*, 2002; Qi *et al*, 2003). Qi *et al* have demonstrated the ability of TIMP-3 to inhibit vascular endothelial growth factor (VEGF)-mediated angiogenesis and identified the possible mechanism involved. In ESCC, VEGF has been reported to be one of the most important angiogenesis factors (Shih *et al*, 2000; Kato *et al*, 2002). Therefore, TIMP-3 may suppress tumour angiogenesis indirectly by inhibiting the VEGF angiogenesis signal, and in turn, tumour growth.

Mori *et al* (2000) investigated TIMP-1 expression of mRNA and protein in ESCC, and reported that TIMP-1 expression is correlated with high-grade malignant behavior, and is an independent prognostic factor. The structure of the protein-coding exons is similar in the *Timp-1* and *Timp-3* genes (Apte *et al*, 1995). Moreover, TIMP-3 and TIMP-1 inhibition were quantitatively similar, implying that all TIMPs are equally efficient in MMP inhibition (Apte *et al*, 1995).

Decreasing expression of TIMP-3 in invasive oesophageal cancer cells may indicate that one of the functions of TIMP-3 is suppression of invasiveness. If cancers having invasive and metastatic ability do not express TIMP-3, preserving or increasing expression of TIMP-3 may lead to a novel cancer therapy. Matrix metalloproteinase inhibitor has recently been developed, and is undergoing trials as an investigational agent (Nozaki *et al*, 2003). Combination therapy with MMP inhibitor and TIMP-3 enhancement may be more effective than MMP inhibitor alone.

In conclusion, decreased expression of TIMP-3 protein correlates with invasive activity and metastasis. This makes the prognosis for patients with cancer that has lost TIMP-3 significantly less favourable than that for patients with cancer that has maintained TIMP-3.

ACKNOWLEDGEMENTS

We thank R Aoyagi for excellent technical assistance, S Ueno, A Nakabayashi, T Ogasawara, H Emura, M Ohnuma and Y Saitoh for their excellent secretarial assistance, and M Ohno for her assistance with the data management and biostatistical analysis. This work was supported, in part, by a Grant-in-Aid for Scientific Research No.15591375 from the Japan Society for the Promotion of Science.

Supplementary information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>).

REFERENCES

- Ahonen MA, Baker AH, Kaharl VM (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. *Cancer Res* **58**: 2310–2315
- Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B, Apte SS (1996) A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. *Biochem Cell Biol* **74**: 853–862
- Anand-Apte B, Pepper MS, Voest E, Montesano R, Olsen B, Murphy G, Apte SS, Zetter B (1997) Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. *Invest Ophthalmol Vis Sci* **38**: 817–823
- Apte SS, Olsen BR, Murphy G (1995) The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. *J Biol Chem* **270**: 14313–14318
- Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. *Cancer Res* **59**: 798–802
- Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. *Br J Cancer* **79**: 1347–1355
- Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, Kung HF, Colburn NH, Sun Y (1996) Suppression of *in vivo* tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. *Carcinogenesis (London)* **17**: 1805–1811
- Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). *J Cell Sci* **107**: 2373–2379
- Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. *FEBS Lett* **298**: 29–32
- Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K, Kuwano H (2002) Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. *Anticancer Res* **22(6C)**: 3977–3984
- Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. *Nature* **284**: 67–68
- Miyagi E, Yasumitsu H, Hirahara F, Minaguchi H, Koshikawa N, Miyazaki K, Umeda M (1995) Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. *Jpn J Cancer Res* **86**: 568–576
- Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K, Ueo H, Barnard GF (2000) Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. *Int J Cancer* **88**: 575–578
- Nozaki S, Sissons S, Chien DS, Sledge Jr GW (2003) Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. *Clin Exp Metast* **20**: 407–412
- Ohashi K, Nemoto T, Nakamura K, Nemori R (2000) Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. *Cancer* **88**: 2201–2209
- Palletier JP, Mineau F, Faure MP, Martel-Pelletier J (1990) Imbalance between the mechanisms of activation and inhibition of metalloproteinases in the early lesions of experimental osteoarthritis. *Arthritis Rheum* **33**: 1466–1476
- Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DR, Hewitt RE (1997) TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. *Br J Cancer* **75**: 1678–1683
- Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. *Nat Med* **9(4)**: 407–415
- Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M (1992) Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. *Oncogene* **7**: 77–83
- Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumor cells. *Nature* **370**: 61–65
- Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M (2000) Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. *Clin Cancer Res* **6(3)**: 1161–1168
- Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, Morimatsu M (1992) Production of matrix metalloproteinase-3 related to malignant behavior of esophageal carcinoma. *Cancer* **70**: 2747–2753
- Spurbeck WW, Ng CY, Strom TS, Vanin EF, Davidoff AM (2002) Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. *Blood* **100(9)**: 3361–3368
- Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. *Annu Rev Cell Biol* **9**: 541–573
- Tryggvason K, Hoyhtya M, Salo T (1987) Proteolytic degradation of extracellular matrix in tumor invasion. *Biochim Biophys Acta* **907**: 191–217
- Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE (1997) Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. *Oncogene* **14**: 2767–2774
- Yang TT, Hawkes SP (1992) Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. *Proc Natl Acad Sci USA* **89**: 10676–10680